文献速递甲状腺疾病

免疫检查点抑制剂治疗未分化甲状腺癌患者临床疗效评估

An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2022-07-20

本文报告13例局部晚期或转移性不可切除未分化甲状腺癌患者接受帕博利珠单抗或纳武利尤单抗治疗的病例系列,中位无进展生存期1.9个月,中位总生存期4.4个月,客观缓解率16%(2/13),1年生存率38%(5/13),46%发生免疫相关不良事件,作者认为免疫检查点抑制可能为有效治疗选择。

要点

  • 13例未分化甲状腺癌患者接受免疫检查点抑制剂治疗,客观缓解率16%(2/13),其中2例部分缓解。
  • 中位无进展生存期1.9个月,中位总生存期4.4个月,1年生存率38%(5/13)。
  • 46%(6/13)发生免疫相关不良事件,15%(2/13)发生≥3级不良事件,包括1例5级免疫检查点相关甲状腺炎。

核心结论

  • 免疫检查点阻断耐受性良好,毒性特征与已发表的PD-1/PD-L1靶向治疗文献一致。
  • 对于未分化甲状腺癌患者,免疫检查点抑制可能代表一种有效的治疗选择,部分患者可见持久持续缓解。

研究设计与样本

  • 单中心病例系列,纳入13例局部晚期或转移性不可切除未分化甲状腺癌患者,接受免疫检查点抑制剂(帕博利珠单抗或纳武利尤单抗)治疗。

主要发现

  • 患者中位年龄70岁,54%(7/13)为男性,85%(11/13)为IVC期,肺和淋巴结为最常见转移部位。
  • 10例有肿瘤组织可行PD-L1表达检测,全部PD-L1阳性,其中7例同时存在BRAFV600E突变。
  • 中位无进展生存期1.9个月,中位总生存期4.4个月,客观缓解率16%(2/13),2例部分缓解,3例持久疾病稳定。
  • 在获得临床获益的患者中,中位随访13.5个月后,中位总生存期未达到(范围4+至29+个月),4例受试者缓解持续。
  • 1年生存率38%(5/13);6例(46%)发生免疫相关不良事件,15%(2/13)发生3级或以上不良事件,包括1例5级免疫检查点相关甲状腺炎。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid malignancy that is associated with poor prognosis. Current treatment options include surgery, radiation, cytotoxic chemotherapy, and multikinase inhibitor therapy. The role of immunotherapy in ATC is an area of active interest and recent evidence suggests that it may be a potentially effective treatment option. Methods: We report a case series of 13 patients with locally advanced or metastatic unresectable ATC who received immune checkpoint inhibitor therapy (pembrolizumab or nivolumab) at a single institution. Results: The patients' median age was 70 years, 54% (7/13) were male, and 85% (11/13) had stage IVC disease with lungs and lymph nodes being the most common sites of metastases. Ten patients had tumor tissue available for programmed death-ligand 1 (PD-L1) expression testing, all of which were positive for PD-L1, and seven of these patients also had a BRAFV600E mutation. The median progression-free survival was 1.9 months and median overall survival (OS) was 4.4 months. The objective response rate was 16% (2/13). Two patients had partial response (PR), and three patients had durable stable disease. Among patients with a clinical benefit, after a median follow-up of 13.5 months, median OS had not been reached (range 4+ to 29+ months). Responses were ongoing in four subjects. The one-year survival rate was 38% (5/13). Six patients (46%) experienced an immune-related adverse event, and 15% (2/13) experienced a grade 3 or higher adverse event, including one patient with grade 5 immune checkpoint-related thyroiditis. Conclusions: Immune checkpoint blockade was well tolerated with a toxicity profile consistent with published literature on PD-1/PD-L1-targeting therapies. For ATC patients, immune checkpoint inhibition may represent an effective treatment option with robust sustained responses seen in a subset of patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Hatashima A, Archambeau B, Armbruster H, et al. An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma. Thyroid. 2022. PMID: 35583228. doi:10.1089/thy.2022.0073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。